Newsletter | August 2, 2022

08.02.22 -- Rapid Method Development: Overcome Bispecific Antibody Purification Challenges

 
CMC Strategy To Take Bispecifics From DNA To IND In 13 Months
 

Review key approaches and technologies that enable an end-to-end comprehensive DS/DP DNA to IND strategy in 13 months, with case study examples for application in vector, process, analytic and formulation development of bispecific molecules during pre-clinical development.

Early Developability And Analytical Toolbox For The Production Of Multichain Biotherapeutics
 

In recent years, the number of biotherapeutic molecules requiring more complex assemblies has greatly increased. Typically, these multichain molecules are no longer compatible with platform approaches and require a more agile approach to early developability and method development.

Rapid Method Development To Overcome Challenges Of Bispecific Antibody Purification
 

While bispecific antibodies (bsAbs) share structural similarities with monoclonal antibodies (mAbs), downstream purification faces challenges with bsAb-specific byproducts. Explore the issues that development scientists encounter and the need for rapid method development.

De-Risk Development And Manufacture Of Bispecific Antibodies With Lonza
 

Assembling and expressing, as well as purifying and analyzing bispecific antibodies to advance them for first-in-human (FIH) trials, comes with a set of unique challenges. Explore how to meet these challenges head-on with a contract development and manufacturing organization (CDMO) that has proven expertise.